Open AccessProfile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
Author(s) -
Wajd Alkabbani,
JohnMichael Gamble
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s281602
Subject(s) - medicine , type 2 diabetes , adverse effect , hypoglycemia , renal glucose reabsorption , intensive care medicine , diabetes mellitus , diabetes management , pharmacology , endocrinology
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes.